BL‐8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open‐label safety and efficacy phase 2a study-Reference-Cited by-同舟云学术

BL‐8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open‐label safety and efficacy phase 2a study

Published:2020-12-03 Issue:8 Volume:127 Page:1246-1259
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Borthakur Gautam¹,Ofran Yishai²,Tallman Martin S.³,Foran James⁴^ORCID,Uy Geoffrey L.⁵,DiPersio John F.⁵,Showel Margaret M.⁶,Shimoni Avichai⁷^ORCID,Nagler Arnon⁷,Rowe Jacob M.⁸,Altman Jessica K.⁹,Abraham Michal¹⁰¹¹,Peled Amnon¹⁰¹¹,Shaw Stephen¹²,Bohana‐Kashtan Osnat¹²,Sorani Ella¹²,Pereg Yaron¹²,Foley‐Comer Adam¹²,Oberkovitz Galia¹²,Lustig Tzipi M.¹²,Glicko‐Kabir Irit¹²,Aharon Arnon¹²,Vainstein‐Haras Abi¹²,Kadosh Shaul E.¹³,Samara Emil¹⁴,Al‐Rawi Ahmed N.¹,Pemmaraju Naveen¹,Bueso‐Ramos Carlos¹,Cortes Jorge E.¹,Andreeff Michael¹

Affiliation:

1. Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas

2. Laboratory of genetic and immunology of Leukemia Rambam Medical Center Haifa Israel

3. Memorial Sloan‐Kettering Cancer Center New York New York

4. Cancer center, Bone Marrow Transplant Program, Hematology Mayo Clinic Jacksonville Florida

5. Oncology Division Bone Marrow Transplantation & Leukemia Washington University School of Medicine St Louis Missouri

6. Johns Hopkins School of Medicine Baltimore Maryland

7. Division of Hematology Chaim Sheba Medical Center Ramat‐Gan Israel

8. Shaare Zedek Medical Center Jerusalem Israel

9. Robert H. Lurie Comprehensive Cancer Center Northwestern University Chicago Illinois

10. Biokine Therapeutics Ltd Ness Ziona Israel

11. Goldyne Savad Institute of Gene TherapyHebrew University Hospital Jerusalem Israel

12. BioLineRx Ltd Modi'in Israel

13. StatExcellence Nesher Israel

14. PharmaPolaris International Inc Washington District of Columbia

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.33338

Reference28 articles.

1. Treatment of Relapsed/Refractory Acute Myeloid Leukemia

2. Relapsed/refractory acute myeloid leukemia: any progress?

3. How I treat refractory and early relapsed acute myeloid leukemia

4. CXCR4Overexpression is a Poor Prognostic Factor in Pediatric Acute Myeloid Leukemia With Low Risk: A Report From the Japanese Pediatric Leukemia/Lymphoma Study Group

5. Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CXCR4 as a therapeutic target in acute myeloid leukemia;Leukemia;2024-09-11

2. CXCL12 chemokine dimer signaling modulates acute myelogenous leukemia cell migration through altered receptor internalization;2024-08-27

3. Targeting cytokine and chemokine signaling pathways for cancer therapy;Signal Transduction and Targeted Therapy;2024-07-22

4. Targeting the bone marrow niche, moving towards leukemia eradication;Frontiers in Hematology;2024-07-22

5. Informed by Cancer Stem Cells of Solid Tumors: Advances in Treatments Targeting Tumor-Promoting Factors and Pathways;International Journal of Molecular Sciences;2024-04-07